Parsabiv regulatory update

FDA approved an NDA from Amgen for Parsabiv etelcalcetide to treat secondary hyperparathyroidism in adults with chronic kidney disease (CKD) on hemodialysis. The company said it would launch Parsabiv “shortly” and announce pricing for the product at that time. Parsabiv is a peptide calcimimetic that acts on the parathyroid gland to reduce production of parathyroid hormone (PTH)...